Clinical Trials Browser

Phase 1/2 × Prostatic Neoplasms × disitamab vedotin × Clear all

NCT06663007 2024-10-29

RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure

Phase 1/2 Recruiting

Prostatic Neoplasms